Section 198 Notification

Hikma Pharmaceuticals Plc
03 November 2006



                            Section 198 Notification

London, 3 November 2006 - On 2 November 2006, Hikma Pharmaceuticals PLC (LSE:
HIK) (DIFX: HIK) ('the Company') received  notification from The Capital Group
Companies, Inc., pursuant to Section 198 Companies Act 1985, that at the close
of  its business on 1 November 2006, The Capital Group Companies, Inc., on
behalf of its affiliates, including Capital  Research and Management Company,
had an interest in 10,223,003 ordinary shares of 10p each in the Company, which 
represents 6.097 per cent of the issued ordinary share capital of the Company,
as follows:

                      No. of shares     Percent of ordinary shares outstanding

The Capital Group
Companies, Inc.          10,223,003                                     6.097%
held as follows:

Capital Research and
Management Company       10,223,003                                     6.097%
of which:

SMALLCAP World Fund,
Inc.                      5,069,153                                     3.023%

New World Fund, Inc.      5,153,850                                     3.074%


Registered holders:
State Street Nominees Limited                                        5,069,153

Chase Nominees Limited                                               5,153,850

                                                 Total              10,223,003


                                    - ENDS -

Enquiries:

Hikma Pharmaceuticals PLC                               [phone]
Henry Knowles, Company Secretary
Susan Ringdal, Investor Relations Director
Brunswick Group LLP                                     [phone]
Jon Coles / Justine McIlroy / Alex Tweed

About Hikma
Hikma Pharmaceuticals PLC is a multinational pharmaceutical group focused on
developing, manufacturing and marketing a broad range of both branded and
non-branded generic and in-licensed pharmaceutical products. Hikma's operations
are conducted through three businesses: Generic, Branded and Injectable
Pharmaceuticals. Hikma's operations are based principally in the United States,
the Middle East and North Africa ('MENA') region and Europe. In 2005, the Group
had revenue of $262 million and profit attributable to shareholders of $44
million. At 31 December 2005, the Group had over 1,800 employees. For news and
other information, please visit www.hikma.com.



                      This information is provided by RNS
            The company news service from the London Stock Exchange
            RLELVIIR